Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SARAH YUE WANG

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1841581931
CMS profile
3670781
Location
TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$10,235.95

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SARAH YUE WANG

NPI 1841581931 · CMS profile ID 3670781

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841581931?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SARAH YUE WANG, NPI 1841581931, CMS profile ID 3670781. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841581931?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SARAH YUE WANG, NPI 1841581931, CMS profile ID 3670781. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841581931?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SARAH YUE WANG, NPI 1841581931, CMS profile ID 3670781, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1841581931?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $10,235.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $27.2106/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206427142 CMS
Tempus AI, Inc $19.9806/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250353130 CMS
Daiichi Sankyo Inc. $25.6606/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197079341 CMS
Daiichi Sankyo Inc. $33.1305/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197083839 CMS
PFIZER INC. $25.0305/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230504974 CMS
AstraZeneca Pharmaceuticals LP $29.2105/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207009239 CMS
SOBI, INC $21.2205/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240278439 CMS
Janssen Biotech, Inc. $31.8605/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175168463 CMS
Novartis Pharmaceuticals Corporation $20.8405/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200565819 CMS
Novartis Pharmaceuticals Corporation $14.1405/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200565821 CMS
Karyopharm Therapeutics Inc. $15.8604/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246651815 CMS
Tempus AI, Inc $27.6604/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250353128 CMS
E.R. Squibb & Sons, L.L.C. $19.7004/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184563703 CMS
Celgene Corporation $35.0004/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184563695 CMS
RECORDATI_RARE_DISEASES_INC. $187.6604/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181725933 CMS
ARRAY BIOPHARMA INC $18.1404/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230495785 CMS
Lilly USA, LLC $14.2804/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186885923 CMS
Janssen Biotech, Inc. $17.2204/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175168414 CMS
Daiichi Sankyo Inc. $113.3304/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197057853 CMS
AstraZeneca Pharmaceuticals LP $26.4304/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206833879 CMS
Daiichi Sankyo Inc. $22.6404/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197059287 CMS
Tempus AI, Inc $19.9603/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250353126 CMS
AstraZeneca Pharmaceuticals LP $24.1603/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206527808 CMS
Stemline Therapeutics Inc. $19.2003/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244106107 CMS
AstraZeneca Pharmaceuticals LP $22.9403/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206638985 CMS
E.R. Squibb & Sons, L.L.C. $19.5102/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184563683 CMS
AstraZeneca Pharmaceuticals LP $28.2702/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206239271 CMS
Geron Corporation $24.4102/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238895855 CMS
AstraZeneca Pharmaceuticals LP $26.6302/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206306033 CMS
Tempus AI, Inc $19.8402/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250353124 CMS
Daiichi Sankyo Inc. $1,110.0002/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1197029185 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.1002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225885601 CMS
Tempus AI, Inc $6.0002/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250353122 CMS
Helsinn Therapeutics (U.S.), Inc. $22.2701/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186334885 CMS
AstraZeneca Pharmaceuticals LP $25.6801/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206546885 CMS
Tempus AI, Inc $8.6901/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250353120 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,403.57 75
PY2020 $142.42 7
PY2021 $3,026.35 20
PY2022 $11,843.77 43
PY2023 $9,757.80 53
PY2024 $14,872.25 117
PY2025 $10,235.95 86

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $389,738.51 117
PY2024 Principal investigator $19,970.99 3
PY2023 Principal investigator $294,160.74 6
PY2022 Principal investigator $460,308.91 19
PY2021 Principal investigator $214,964.44 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

117 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $564.36 12/31/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
KEYMAKER-U01 Substudy 01E# A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II IIIB N2 Non-small Cell No dispute reported 06/30/2026 1232924999
Principal investigator 1 Amgen Inc. $51,500.00 12/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTION LLC
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) No dispute reported 06/30/2026 1246647913
Principal investigator 1 Amgen Inc. $28,600.00 12/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTION LLC
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1246647963
Principal investigator 1 Daiichi Sankyo Inc. $123.00 12/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382072
Principal investigator 1 Daiichi Sankyo Inc. $116.00 12/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382100
Principal investigator 1 ABBVIE INC. $2,292.30 12/04/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202527316
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328052
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382070
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382078
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382088
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382092
Principal investigator 1 Daiichi Sankyo Inc. $5,166.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382096
Principal investigator 1 Daiichi Sankyo Inc. $379.00 11/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382098
Principal investigator 1 Janssen Research & Development, LLC $17,000.00 11/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329458
Principal investigator 1 ABBVIE INC. $2,292.30 11/05/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202523137
Principal investigator 1 Daiichi Sankyo Inc. $1,316.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382074
Principal investigator 1 Daiichi Sankyo Inc. $1,193.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382076
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382080
Principal investigator 1 Daiichi Sankyo Inc. $1,193.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382082
Principal investigator 1 Daiichi Sankyo Inc. $1,316.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382094
Principal investigator 1 Daiichi Sankyo Inc. $1,193.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382104
Principal investigator 1 Daiichi Sankyo Inc. $1,193.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382106
Principal investigator 1 Daiichi Sankyo Inc. $1,512.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382108
Principal investigator 1 Daiichi Sankyo Inc. $115.00 10/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382084
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 10/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382086
Principal investigator 1 Daiichi Sankyo Inc. $2,175.00 10/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382090
Principal investigator 1 Daiichi Sankyo Inc. $379.00 10/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382102
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 10/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382110
Principal investigator 1 Daiichi Sankyo Inc. $3,839.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382044
Principal investigator 1 Daiichi Sankyo Inc. $2,388.00 09/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382068
Principal investigator 1 Daiichi Sankyo Inc. $5,000.00 09/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382030
Principal investigator 1 Daiichi Sankyo Inc. $15,000.00 09/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382032
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382036
Principal investigator 1 Daiichi Sankyo Inc. $570.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382038
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382040
Principal investigator 1 Daiichi Sankyo Inc. $3,051.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382042
Principal investigator 1 Daiichi Sankyo Inc. $2,596.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382062
Principal investigator 1 Daiichi Sankyo Inc. $6,900.00 09/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382034
Principal investigator 1 Daiichi Sankyo Inc. $3,500.00 09/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382064
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382046
Principal investigator 1 Daiichi Sankyo Inc. $6,000.00 09/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382048
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385285
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385287
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385289
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385291
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385293
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385295
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385297
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385299
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385301
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385303
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385305
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385307
Principal investigator 1 Daiichi Sankyo Inc. $5,130.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382050
Principal investigator 1 Daiichi Sankyo Inc. $6,291.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382052
Principal investigator 1 Daiichi Sankyo Inc. $6,291.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382054
Principal investigator 1 Daiichi Sankyo Inc. $2,928.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382056
Principal investigator 1 Daiichi Sankyo Inc. $2,928.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382058
Principal investigator 1 Daiichi Sankyo Inc. $5,549.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382060
Principal investigator 1 Daiichi Sankyo Inc. $3,644.00 08/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS7300-188 No dispute reported 06/30/2026 1223382066
Principal investigator 1 ABBVIE INC. $19,000.00 05/07/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202482765
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $107,934.34 05/06/2025 Non-covered Recipient Entity
Texas Oncology Tyler
Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) No dispute reported 06/30/2026 1235993209
Principal investigator 1 Daiichi Sankyo Inc. $4.25 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385045
Principal investigator 1 Daiichi Sankyo Inc. $50.15 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385047
Principal investigator 1 Daiichi Sankyo Inc. $50.15 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385049
Principal investigator 1 Daiichi Sankyo Inc. $50.15 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385051
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385053
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385055
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385057
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385059
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385061
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385063
Principal investigator 1 Daiichi Sankyo Inc. $91.25 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385065
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385067
Principal investigator 1 Daiichi Sankyo Inc. $4.25 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385069
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385071
Principal investigator 1 Daiichi Sankyo Inc. $91.25 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385073
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385075
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385077
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385079
Principal investigator 1 Daiichi Sankyo Inc. $86.30 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385081
Principal investigator 1 Daiichi Sankyo Inc. $86.30 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385083
Principal investigator 1 Daiichi Sankyo Inc. $86.30 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385085
Principal investigator 1 Daiichi Sankyo Inc. $75.00 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385087
Principal investigator 1 Daiichi Sankyo Inc. $75.00 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385089
Principal investigator 1 Daiichi Sankyo Inc. $154.65 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385091
Principal investigator 1 Daiichi Sankyo Inc. $154.65 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385093
Principal investigator 1 Daiichi Sankyo Inc. $154.65 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385095
Principal investigator 1 Daiichi Sankyo Inc. $44.70 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385097
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385099
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385101
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385103
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385105
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385107
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385109
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385111
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385113
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385115
Principal investigator 1 Daiichi Sankyo Inc. $4.25 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385117
Principal investigator 1 Daiichi Sankyo Inc. $30.80 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385119
Principal investigator 1 Daiichi Sankyo Inc. $29.25 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385121
Principal investigator 1 Daiichi Sankyo Inc. $29.25 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385123
Principal investigator 1 Daiichi Sankyo Inc. $30.80 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385125
Principal investigator 1 Daiichi Sankyo Inc. $29.25 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385127
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385129
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385131
Principal investigator 1 Daiichi Sankyo Inc. $44.70 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385133
Principal investigator 1 Daiichi Sankyo Inc. $91.25 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385135
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385137
Principal investigator 1 Daiichi Sankyo Inc. $75.00 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385139
Principal investigator 1 Daiichi Sankyo Inc. $30.80 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385141
Principal investigator 1 Daiichi Sankyo Inc. $44.70 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385143
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/11/2025 Non-covered Recipient Entity
Texas Oncology - Northeast Texas
DS7300-188 No dispute reported 06/30/2026 1223385145
Principal investigator 1 Amgen Inc. $9,000.00 02/28/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY NORTHEAST TEXAS
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) No dispute reported 06/30/2026 1246649301
Principal investigator 1 Amgen Inc. $16,697.52 02/25/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY NORTHEAST TEXAS
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1246649305
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $588.64 02/25/2025 Non-covered Recipient Entity
Texas Oncology Tyler
Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) No dispute reported 06/30/2026 1235993211
Principal investigator 1 Merck Sharp & Dohme LLC $2,500.00 02/21/2025 Covered Recipient Teaching Hospital
Parkview Hospital
A Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participants with treatment-na ve, metastatic nonsmall cell lung cancer NSCLC whose tumors have a tumor proportion score TPS greater tha No dispute reported 06/30/2026 1232936788